Literature DB >> 18463319

Mineral arsenicals in traditional medicines: orpiment, realgar, and arsenolite.

Jie Liu1, Yuanfu Lu, Qin Wu, Robert A Goyer, Michael P Waalkes.   

Abstract

Mineral arsenicals have long been used in traditional medicines for various diseases, yet arsenic can be highly toxic and carcinogenic. Arsenic in traditional medicines typically comes from deliberate addition for therapeutic purposes, mainly in the form of mineral arsenicals, including orpiment (As2S3), realgar (As4S4), and arsenolite (contains arsenic trioxide, As2O3). Inorganic arsenic is now accepted in Western medicine as a first line chemotherapeutic agent against certain hematopoietic cancers. This perspective analyzes the pharmacology and toxicology of these arsenicals used in traditional medicines. Orpiment and realgar are less soluble and poorly absorbed from the gastrointestinal tract, whereas the bioavailability of arsenic trioxide is similar to inorganic arsenic salts such as sodium arsenite. Pharmacological studies show that arsenic trioxide and realgar are effective against certain malignancies. Orpiment and realgar are used externally for various skin diseases. Realgar is frequently included as an ingredient in oral traditional remedies for its antipyretic, anti-inflammatory, antiulcer, anti-convulsive, and anti-schistosomiasis actions, but the pharmacological basis for this inclusion still remains to be fully justified. Toxicological studies show that cardiovascular toxicity is the major concern for arsenic trioxide and that the gastrointestinal and dermal adverse effects may occur after prolonged use of mineral arsenicals. Little is known regarding the possible secondary cancers resulting from the long-term use of any of these arsenicals. Similar to the safety evaluation of seafood arsenicals, total arsenic content alone appears to be insufficient for mineral arsenical safety evaluation. Arsenic speciation, bioavailability, and toxicity/benefit should be considered in evaluation of mineral arsenical-containing traditional medicines.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18463319      PMCID: PMC2693900          DOI: 10.1124/jpet.108.139543

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  34 in total

1.  Bhasmas: unique ayurvedic metallic-herbal preparations, chemical characterization.

Authors:  A Kumar; A G C Nair; A V R Reddy; A N Garg
Journal:  Biol Trace Elem Res       Date:  2006-03       Impact factor: 3.738

2.  [Chronic arsenic poisoning caused by long-term taken Niuhuang Ninggong tablet: a report of 2 cases].

Authors:  Li-min Wang
Journal:  Zhongguo Zhong Xi Yi Jie He Za Zhi       Date:  2005-03

Review 3.  Acute promyelocytic leukemia: recent advances in therapy and molecular basis of response to arsenic therapies.

Authors:  Wen-Chien Chou; Chi V Dang
Journal:  Curr Opin Hematol       Date:  2005-01       Impact factor: 3.284

4.  Survival after a lethal dose of arsenic trioxide.

Authors:  Barbara Vantroyen; J F Heilier; Agnes Meulemans; Arnold Michels; J P Buchet; Steven Vanderschueren; V Haufroid; Marc Sabbe
Journal:  J Toxicol Clin Toxicol       Date:  2004

5.  Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients.

Authors:  Z X Shen; G Q Chen; J H Ni; X S Li; S M Xiong; Q Y Qiu; J Zhu; W Tang; G L Sun; K Q Yang; Y Chen; L Zhou; Z W Fang; Y T Wang; J Ma; P Zhang; T D Zhang; S J Chen; Z Chen; Z Y Wang
Journal:  Blood       Date:  1997-05-01       Impact factor: 22.113

6.  Tumorigenicity of inorganic arsenic compounds following intratracheal instillations to the lungs of hamsters.

Authors:  A Yamamoto; A Hisanaga; N Ishinishi
Journal:  Int J Cancer       Date:  1987-08-15       Impact factor: 7.396

7.  Solubility, retention, and metabolism of intratracheally and orally administered inorganic arsenic compounds in the hamster.

Authors:  E Marafante; M Vahter
Journal:  Environ Res       Date:  1987-02       Impact factor: 6.498

8.  Induction of metallothionein by arsenicals in mice.

Authors:  H Kreppel; J W Bauman; J Liu; J M McKim; C D Klaassen
Journal:  Fundam Appl Toxicol       Date:  1993-02

9.  Effect of arsenic exposure on alveolar macrophage function. II. Effect of slightly soluble forms of As(III) and As(V).

Authors:  R C Lantz; G Parliman; G J Chen; D Barber; S Winski; D E Carter
Journal:  Environ Res       Date:  1995-01       Impact factor: 6.498

10.  Arsenite as the probable active species in the human carcinogenicity of arsenic: mouse micronucleus assays on Na and K arsenite, orpiment, and Fowler's solution.

Authors:  H Tinwell; S C Stephens; J Ashby
Journal:  Environ Health Perspect       Date:  1991-11       Impact factor: 9.031

View more
  36 in total

1.  Comparing the relative oxidative DNA damage caused by various arsenic species by quantifying urinary levels of 8-hydroxy-2'-deoxyguanosine with isotope-dilution liquid chromatography/mass spectrometry.

Authors:  Jin-Zhu Wu; Paul C Ho
Journal:  Pharm Res       Date:  2009-03-06       Impact factor: 4.200

2.  Bioaccessibility of lead and arsenic in traditional Indian medicines.

Authors:  Iris Koch; Maeve Moriarty; Kim House; Jie Sui; William R Cullen; Robert B Saper; Kenneth J Reimer
Journal:  Sci Total Environ       Date:  2011-08-23       Impact factor: 7.963

3.  Determination of in vitro bioaccessibility of Pb, As, Cd and Hg in selected traditional Indian medicines.

Authors:  Innocent Jayawardene; Robert Saper; Nicola Lupoli; Anusha Sehgal; Robert O Wright; Chitra Amarasiriwardena
Journal:  J Anal At Spectrom       Date:  2010       Impact factor: 4.023

4.  Heavy metal and pesticide content in commonly prescribed individual raw Chinese Herbal Medicines.

Authors:  Eric S J Harris; Shugeng Cao; Bruce A Littlefield; Jane A Craycroft; Robert Scholten; Ted Kaptchuk; Yanling Fu; Wenquan Wang; Yong Liu; Hubiao Chen; Zhongzhen Zhao; Jon Clardy; Alan D Woolf; David M Eisenberg
Journal:  Sci Total Environ       Date:  2011-08-06       Impact factor: 7.963

5.  Realgar quantum dots induce apoptosis and necrosis in HepG2 cells through endoplasmic reticulum stress.

Authors:  Y U Qin; Huan Wang; Zheng-Yun Liu; Jie Liu; Jin-Zhu Wu
Journal:  Biomed Rep       Date:  2015-07-15

Review 6.  Disruption of Mitotic Progression by Arsenic.

Authors:  J Christopher States
Journal:  Biol Trace Elem Res       Date:  2015-03-22       Impact factor: 3.738

7.  Organoarsenicals inhibit bacterial peptidoglycan biosynthesis by targeting the essential enzyme MurA.

Authors:  Luis D Garbinski; Barry P Rosen; Masafumi Yoshinaga
Journal:  Chemosphere       Date:  2020-04-27       Impact factor: 7.086

8.  Arsenic exposure predicts bladder cancer survival in a US population.

Authors:  Ryan C Kwong; Margaret R Karagas; Karl T Kelsey; Rebecca A Mason; Sam A Tanyos; Alan R Schned; Carmen J Marsit; Angeline S Andrew
Journal:  World J Urol       Date:  2009-10-16       Impact factor: 4.226

9.  Anticancer effect of realgar nanoparticles on mouse melanoma skin cancer in vivo via transdermal drug delivery.

Authors:  Qi-Hong Zhao; Ying Zhang; Yun Liu; Hui-Li Wang; Yuan-Yuan Shen; Wen-Jun Yang; Long-Ping Wen
Journal:  Med Oncol       Date:  2009-03-12       Impact factor: 3.064

10.  Effects of Glycyrrhetinic Acid on GSH Synthesis Induced by Realgar in the Mouse Hippocampus: Involvement of System [Formula: see text], System [Formula: see text], MRP-1, and Nrf2.

Authors:  Yan-Lei Wang; Mo Chen; Tao-Guang Huo; Ying-Hua Zhang; Ying Fang; Cong Feng; Shou-Yun Wang; Hong Jiang
Journal:  Mol Neurobiol       Date:  2016-04-02       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.